Amgen at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

Amgen brings 4 presentations to ObesityWeek 2026 in National Harbor, and exhibits at Booth 501, Suite 22, Suite 23. Its program spans the treatment journey with GLP-1 drugs, including medical costs by whether patients stay on therapy, and mouse studies comparing blocking and activating the GIP receptor. It also tests how well BMI matches central fat and body composition in UK Biobank.

OrganizationObesityWeek 2026 Attendance
Amgen
Thousand Oaks, CA
◆Silver Sponsor
Large pharmaSilver Sponsor
Biotechnology company drawing on biology, technology and human genetic data to develop medicines for serious diseases.
Booth
Exhibiting at Booth 501, Suite 22, Suite 23
Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm
Poster
Sat Nov 14
7:30pm–8:30pm
Talk
Sun Nov 15
7:30am–8:30am
The Obesity Treatment Journey: Evaluating Burden, Discontinuation, and Outcomes
Uses a patient case and real-world data to examine why patients stop obesity treatment, what follows, and care changes that keep people on therapy.
Riverview Ballroom B
with knownwell, UT Southwestern Medical Center
Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practicePolicy and public healthNutrition, diet and foodChronic disease and obesity complicationsNeuroscience of appetite and eatingObesity pharmacotherapy and drug development

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Amgen

Tell us what you sell and we’ll find the people at Amgen most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction